Study #2023-0006
A randomized trial of maintenance Systemic Therapy after Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
MD Anderson Study Status
Enrolling
Treatment Agent
Pembrolizumab
Description
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Oligometastatic Renal Cell Carcinoma
Study phase:
Phase II
Physician name:
Chad Tang
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.